We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+15.28%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.15B
AUM Growth
-$394M
(-15%)
Cap. Flow
-$894M
Cap. Flow
% of AUM
-41.57%
Top 10 Holdings %
Top 10 Hldgs %
42.88%
Holding
116
New
14
Increased
12
Reduced
29
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVRO
NEVRO CORP.
NVRO
|
+$48.4M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$46.1M |
| 3 |
TSRO
TESARO, Inc.
TSRO
|
+$22.6M |
| 4 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$21.3M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$17.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$143M |
| 2 |
XNPT
XENOPORT, INC.
XNPT
|
+$81.5M |
| 3 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$49.8M |
| 4 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
+$35.4M |
| 5 |
Vanda Pharmaceuticals
VNDA
|
+$34.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.12% |
| 2 | Financials | 3.34% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GWPH
1
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $134M | 6.23% |
1,008,475
+16,675
| +2% | +$1.59M |
|
|
PTLA
2
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $128M | 5.96% |
5,639,727
+1,966,000
| +54% | +$46.1M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $117M | 5.43% |
6,434,439
-7,305,822
| -53% | -$143M |
|
|
NXTM
4
DELISTED
NxStage Medical Inc.
NXTM
| $102M | 4.76% |
4,099,175
-406,293
| -9% | -$9.47M |
|
|
AVXS
5
DELISTED
AveXis, Inc. Common Stock
AVXS
| $92.2M | 4.29% |
2,236,701
| – | – |
|
|
ADPT
6
DELISTED
Adeptus Health Inc
ADPT
| $68.9M | 3.21% |
1,600,861
| – | – |
|
|
DBVT
7
DBV Technologies
DBVT
$870M
| $63.3M | 2.95% |
174,323
| – | – |
|
|
8
Vanda Pharmaceuticals
VNDA
$327M
| $57.2M | 2.66% |
3,435,576
-2,561,115
| -43% | -$34.5M |
|
|
NVRO
9
DELISTED
NEVRO CORP.
NVRO
| $56M | 2.6% |
+536,355
| New | +$48.4M |
|
10
Viatris
VTRS
$20.1B
| $54.3M | 2.52% |
1,423,334
+84,000
| +6% | +$3.73M |
|
11
Xencor
XNCR
$1.3B
| $54.1M | 2.52% |
2,210,900
-719,586
| -25% | -$15.2M |
|
|
AERI
12
DELISTED
Aerie Pharmaceuticals
AERI
| $50.5M | 2.35% |
1,338,829
-1,181,756
| -47% | -$26.1M |
|
|
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
| $50.5M | 2.35% |
4,072,809
| – | – |
|
|
AET
14
DELISTED
Aetna Inc
AET
| $42.3M | 1.97% |
366,000
| – | – |
|
|
AAC
15
DELISTED
AAC Holdings
AAC
| $38.1M | 1.77% |
2,189,849
+40,147
| +2% | +$791K |
|
|
UAM
16
DELISTED
Universal American Corp
UAM
| $35.1M | 1.63% |
4,592,060
+269,060
| +6% | +$1.99M |
|
|
ALPN
17
DELISTED
Alpine Immune Sciences Inc
ALPN
| $30.3M | 1.41% |
933,103
| – | – |
|
18
eHealth
EHTH
$47.3M
| $29.6M | 1.38% |
2,640,609
| – | – |
|
|
WBA
19
DELISTED
Walgreens Boots Alliance
WBA
| $28.7M | 1.33% |
355,957
-255,500
| -42% | -$20.8M |
|
20
Humana
HUM
$48B
| $28.2M | 1.31% |
159,500
| – | – |
|
|
LKFT
21
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
| $27.4M | 1.27% |
423,112
-35,000
| -8% | -$1.97M |
|
|
SYRS
22
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $25.1M | 1.17% |
181,278
-28,244
| -13% | -$3.58M |
|
|
BOLD
23
DELISTED
Audentes Therapeutics, Inc
BOLD
| $25M | 1.16% |
+1,403,653
| New | +$21.3M |
|
|
TSRO
24
DELISTED
TESARO, Inc.
TSRO
| $24.3M | 1.13% |
+242,300
| New | +$22.6M |
|
25
DaVita
DVA
$15.2B
| $23.1M | 1.08% |
350,000
-175,000
| -33% | -$12.3M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2016 Portfolio in Review
As of Q3 2016, Deerfield Management held 116 positions worth $2.15B, down 15% from $2.54B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Deerfield Management withdrew a net $894M in Q3 2016, closing 26 positions and reducing 29 holdings. Its most notable exit was XENOPORT, INC., an estimated $81.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.
Against the trend, Deerfield Management opened a new position in NEVRO CORP. worth $56M.
- Deerfield Management's largest Q3 2016 buy was NEVRO CORP.: 536,355 shares worth $56M.
- Deerfield Management added most to Portola Pharmaceuticals, Inc. in Q3 2016, an estimated $46.1M increase.
- Deerfield Management's biggest Q3 2016 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $143M.
- Deerfield Management fully exited XENOPORT, INC. in Q3 2016, selling an estimated $81.5M.
- Deerfield Management's ten largest holdings make up 43% of its $2.15B portfolio in Q3 2016.
- Deerfield Management opened 14 new positions and closed 26 in Q3 2016.
- Deerfield Management's portfolio value fell 15% quarter-over-quarter to $2.15B.
Based on Deerfield Management's 13F filing for Q3 2016, filed 14 Nov 2016.